KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease.

Stephen Salloway, Andrew Pain, Elly Lee, Michelle Papka, Margaret B Ferguson, Hong Wang, Haoyan Hu, Ming Lu, Ena Oru, Paul A Ardayfio, Deirdre B Hoban, Emily C Collins, Dawn A Brooks, John R Sims

Alzheimers Dement 21(5) e70293

PMID40390253
PMCIDPMC12089073
DOI10.1002/alz.70293
发表日期2025-05-20
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

INTRODUCTION: The phase 3, open-label TRAILBLAZER-ALZ 4 study compared the effect of donanemab versus aducanumab on amyloid plaque (AP) clearance in participants with early symptomatic Alzheimer's disease. METHODS: Participants (n = 148) were randomized 1:1 to receive intravenous donanemab (700 mg every 4 weeks for three doses, then 1400 mg every 4 weeks thereafter) or aducanumab (per label). AP was measured with florbetapir F 18 positron emission tomography. AP clearance was defined as < 24.1 Centiloids. RESULTS: At 6, 12, and 18 months, AP clearance was achieved in 37.9%, 70.0%, and 76.8%, respectively, of donanemab-treated participants versus 1.6%, 24.6%, and 43.1% of aducanumab-treated participants (P < 0.001). Median time to clearance was 359 versus 568 days for donanemab- versus aducanumab-treated participants (P < 0.001). Amyloid-related imaging abnormality (ARIA)-edema/effusion occurred in 23.9% and 34.8% of donanemab- and aducanumab-treated participants, respectively. DISCUSSION: Donanemab treatment resulted in earlier and greater AP clearance compared to aducanumab. ARIA frequencies were consistent with prior studies. CLINICAL TRIAL REGISTRATION: No: NCT05108922, TRAILBLAZER-ALZ 4 HIGHLIGHTS: Here we report the first direct comparator study of two amyloid-targeting therapies. This was the first investigation of donanemab on biomarker efficacy regardless of tau levels. Donanemab demonstrated superiority over aducanumab in amyloid plaque (AP) clearance. The depth and speed of AP removal did not affect amyloid-related imaging abnormality risk or incidence.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。